<DOC>
	<DOCNO>NCT02417311</DOCNO>
	<brief_summary>Heart failure ( HF ) common end-stage different medical condition . It grow cardiovascular disease prognosis remain bad many malignancy . The lack evidence-based treatment patient diastolic HF ( HFpEF ) exemplify current `` one '' therapy advance individualized approach . Inherited cardiomyopathy serve paradigmatic example different HF pathogenesis . Both gain- loss-of-function mutation gene cause disease , call disease-specific agonism antagonism gene´s function . However , mutation alone predict severity cardiomyopathy therapy , impact cardiac myocyte function modify numerous factor , include genetic context . Today , patient-specific cardiac myocytes evaluate induced pluripotent stem cell ( hiPSC ) technology . Yet , unfold true potential technology require robust , quantitative , high content assay . The researcher ' recently develop method generate 3D-engineered heart tissue ( EHT ) hiPSC provide automate , high content analysis heart muscle function response stressor dish . The aim project make technology clinically applicable test . Major step ( ) depths clinical phenotyping genotyping patient cardiomyopathy HFpEF , ( ii ) follow-up clinical course , ( iii ) generation hiPSC line ( 40 patient , 40 healthy control ) , ( iv ) quantitative assessment hiPSC-EHT function basal condition response pro-arrhythmic cardio-active drug chronic afterload enhancement . The product study SOP-based assay standard value hiPSC-EHT function/stress response healthy volunteer patient different heart disease . The project could change clinical practice step towards individualize risk prediction therapy HF .</brief_summary>
	<brief_title>Individualized Early Risk Assessment Heart Diseases</brief_title>
	<detailed_description>At present , heart function patient analyse image method hemodynamic measurement . This dramatically change discovery hiPSC generate somatic cell ( e.g . fibroblast ) transduction pluripotency gene . The investigator others show pluripotent stem cell efficiently differentiate beat cardiac myocytes . This allow first time study function cardiac myocytes individual patient . However , present , alteration reproduce hiPSC cell know previously important limitation resolve : - Immaturity hiPSC-derived cardiac myocytes - Variability hiPSC-generation , cardiac myocyte differentiation experimental analyse - No readout contractile force , parameter mostly affect heart failure - No model hemodynamic stress vitro - No statistically valid correlation hiPSC-cardiac myocyte function clinical/genetic data - Uncertainty standard value adequate control - Unclear predictive value The research challenge come year resolve shortcoming . IndivuHeart formulate number hypothesis goal base researcher ' longstanding expertise tissue engineering recent , still unpublished data pathophysiology HCM modeling EHT . The study - reveal standard value hiPSC-EHT function statistically valid manner , basal stress condition , - define `` cardiomyopathy phenotype '' vitro , - allow new mechanistic insight pathogenesis human HCM DCM , - uncover HCM-like abnormality HFpEF , - allow individualized drug testing ( acute chronic ) .</detailed_description>
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Cardiomyopathies</mesh_term>
	<mesh_term>Hypertrophy</mesh_term>
	<mesh_term>Cardiomyopathy , Dilated</mesh_term>
	<mesh_term>Cardiomyopathy , Hypertrophic</mesh_term>
	<criteria>HCM : ProBNP ≥ 300 ng/l ; IVSd ≥ 20 mm ; E/E´ ≥ 8 , LVOT &gt; 30 mmHg DCM : presence sign and/or symptom HF ( NYHA IIIV ) ; ProBNP ≥ 300 ng/l ; LV EF ≤ 40 % &gt; 3 month Uncontrolled hypertension , coronary artery disease , persistent atrial fibrillation , enlist myectomy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Engineered Heart Tissue ( EHT )</keyword>
	<keyword>human induce pluripotent stem cell ( hiPSC )</keyword>
</DOC>